Effect of amalaki swarasa bhavita haridra churna in patients with diabetic dyslipidemia.
Phase 1
Not yet recruiting
- Conditions
- Health Condition 1: E889- Metabolic disorder, unspecified
- Registration Number
- CTRI/2023/07/054879
- Lead Sponsor
- Ashna Noushad
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1) Type 2 diabetes mellitus with :
a) FBS more than 110mg/dl and less than 200 mg/dl.
b) PPBS greater than 140 mg/dl and less than 240 mg/dl.
c) HbA1C in range of 6.5 to 8.
2) LDL in the range 130 mg/dl and above.
3) Individuals ready to follow all procedures.
Exclusion Criteria
1) Individuals with known history of cardiac pathology, Chronic kidney disease, liver pathologies and hematological disorders.
2) Individuals with known history of any other endocrinological disease like hypothyroidism, aldosteronism etc.
3) Pregnant and lactating females.
4) Participants who are already administering medication for dyslipidemia and diabetes.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of diabetic dyslipidemia by reduction in LDL, FBS, PPBS and HbA1C.Timepoint: Assessment of LDL, FBS, & PPBS on before treatment, after 1st month, after 2nd month and after 3rd month. <br/ ><br>Assessment of HbA1C on before treatment and after treatment. <br/ ><br>Total course of intervention - 3months.
- Secondary Outcome Measures
Name Time Method Antidiabetic & anti hyperlipidemic effect of amalaki swarasa bhavita haridra churna.Timepoint: Assessment of LDL, FBS, & PPBS on before treatment, after 1st month, after 2nd month & after 3rd month. <br/ ><br>Assessment of HbA1C on before treatment & after treatment. <br/ ><br>Total course of intervention- 3 months